




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> C07D 451/00, 451/04, 451/06 C07D 451/14, 453/02, 453/06 C07D 487/08, 498/08 A61K 31/395, 31/435	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/10494</b>  <b>(43) International Publication Date:</b> 25 June 1992 (25.06.92)
<b>(21) International Application Number:</b> PCT/GB91/02173  <b>(22) International Filing Date:</b> 6 December 1991 (06.12.91)  <b>(30) Priority data:</b> 9027098.4 13 December 1990 (13.12.90) GB  <b>(71) Applicant (for all designated States except US):</b> BEECHAM GROUP P.L.C. [GB/GB]; Four New Horizons Court, Harlequi Avenue, Brentford, Middlesex TW8 9EP (GB).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only) :</b> KING, Francis, David [GB/GB]; SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex CM19 5AD (GB).		<b>(74) Agents:</b> JONES, Pauline et al.; SmithKline Beecham, Corporate Patents, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).  <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i>

**(54) Title:** PHARMACEUTICALS

(I)

**(57) Abstract**

Compounds of formula (I) and pharmaceutically acceptable salts thereof wherein the variable groups are as defined in the specification.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU <sup>+</sup>	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

-1-

PHARMACEUTICALS

This invention relates to novel compounds having pharmacological activity, to a process for their preparation and their use as pharmaceuticals.


UK Patent No. 1571447 (Societe D'Etudes Scientifiques et Industrielles de L'Ile-de-France) describes a group of benzamide derivatives having dopamine antagonist activity.

10

A group of novel compounds have now been discovered, which compounds are 5-HT<sub>3</sub> receptor antagonists.

Accordingly, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof:

20



(I)

wherein

$\text{R}_1$  is hydrogen, halo, nitro, amino,  $\text{C}_{1-6}$  alkyl or  $\text{C}_{1-6}$  alkoxy;

$\text{R}_2$  is halo,  $\text{C}_{1-6}$  alkyl or  $\text{C}_{1-6}$  alkoxy;

A is (poly)methylene of 1-3 carbon atoms, optionally substituted by one or two  $\text{C}_{1-6}$  alkyl group(s);

L is O or NH; and

Z is a di-azacyclic or azabicyclic side chain; having 5-HT<sub>3</sub> receptor antagonist activity.

-2-

Suitable examples of alkyl moieties in  $R_1$  and  $R_2$  and A include methyl, ethyl, n- and iso-propyl, n-, iso-, sec- and tert-butyl.

- 5 Suitable examples of halo moieties include fluoro, chloro and bromo, preferably chloro or bromo.

Often  $R_1$  is hydrogen and  $R_2$  is chloro or bromo.

- 10 A is preferably unsubstituted polymethylene of 1 or 2 carbon atoms (i.e. O-A-O is methylenedioxy or ethylenedioxy).

Suitable examples of Z are described in the art relating to 5-HT<sub>3</sub> receptor antagonists, ie. as follows:

15

- i) GB 2125398A (Sandoz Limited)
- ii) GB 2152049A (Sandoz Limited)
- iii) EP-A-215545 (Beecham Group p.l.c.)
- iv) EP-A-214772 (Beecham Group p.l.c.)
- 20 v) EP-A-377967 (Beecham Group p.l.c.)
- vi) PCT/GB91/01629 (Beecham Group p.l.c.)
- vii) EP-A-358903 (Dianippon)

Particular side chains of interest are depicted thus:

25


Tropane

30




Granatane

35



Oxa/thia/aza-granatane

5

Quinuclidine

10

15 Isoquinuclidine

20

Isogranatane

25

Oxa/thia-isogranatane

30



35

Isotropane

5



or



wherein

R is hydrogen or methyl; and X is oxygen, sulphur or  
 10 nitrogen optionally substituted by C<sub>1-6</sub> alkyl, C<sub>3-8</sub>  
 cycloalkyl, C<sub>3-8</sub> cycloalkyl C<sub>1-4</sub> alkyl, phenyl, naphthyl,  
 phenyl C<sub>1-4</sub> alkyl or naphthyl C<sub>1-4</sub> alkyl wherein a phenyl or  
 naphthyl moiety is optionally substituted by one or more of  
 halo, C<sub>1-6</sub> alkoxy or C<sub>1-6</sub> alkyl.

15

Side chains Z of particular interest include tropene,  
 oxagranatane and azagranatane, where R is methyl. Suitable  
 values for N-substituents when X is N are as described in  
 PCT/GB91/01629, for example, iso-propyl or ethyl.

20

L is preferably NH.

Alternatively, COL in formula (I) may be replaced by a  
 bioisostere therefor, for example, 1,2,4-oxadiazole and the  
 25 other groups of structure h) described in EP-A-377967  
 (Beecham Group p.l.c.).

The pharmaceutically acceptable salts of the compounds of  
 the formula (I) include acid addition salts with  
 30 conventional acids such as hydrochloric, hydrobromic, boric,  
 phosphoric, sulphuric acids and pharmaceutically acceptable  
 organic acids such as acetic, tartaric, maleic, citric,  
 succinic, benzoic, ascorbic, methanesulphonic,  $\alpha$ -keto  
 glutaric,  $\alpha$ -glycerophosphoric, and glucose-1-phosphoric  
 35 acids.

-5-

The pharmaceutically acceptable salts of the compounds of the formula (I) are usually acid addition salts with acids such as hydrochloric, hydrobromic, phosphoric, sulphuric, citric, tartaric, lactic and acetic acid.

5

Preferably the acid addition salt is the hydrochloride salt.

Examples of pharmaceutically acceptable salts include quaternary derivatives of the compounds of formula (I) such  
10 as the compounds quaternised by compounds  $R_x-T$  wherein  $R_x$  is  $C_{1-6}$  alkyl, phenyl- $C_{1-6}$  alkyl or  $C_{5-7}$  cycloalkyl, and T is a radical corresponding to an anion of an acid. Suitable examples of  $R_x$  include methyl, ethyl and n- and iso-propyl; and benzyl and phenethyl. Suitable examples of T include  
15 halide such as chloride, bromide and iodide.

Examples of pharmaceutically acceptable salts also include internal salts such as N-oxides.


20 The compounds of the formula (I), their pharmaceutically acceptable salts, (including quaternary derivatives and N-oxides) may also form pharmaceutically acceptable solvates, such as hydrates, which are included wherever a compound of formula (I) or a salt thereof is herein referred  
25 to.

It will of course be realised that some of the compounds of the formula (I) have chiral or prochiral centres and thus are capable of existing in a number of stereoisomeric forms  
30 including enantiomers. The invention extends to each of these stereoisomeric forms (including enantiomers), and to mixtures thereof (including racemates). The different stereoisomeric forms may be separated one from the other by the usual methods.

35

-6-

The invention also provides a process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, which process comprises reacting a compound of formula (II):



(II)

with a compound of formula (III):

HLZ'

(III)

or a reactive derivative thereof, when L is O;

wherein  $\text{R}_1'$ ,  $\text{R}_2'$  and/or Z' are  $\text{R}_1$ ,  $\text{R}_2$  and/or Z respectively or groups or atoms convertible thereto;  $\text{Q}_1$  is a leaving group; and the remaining variables are as hereinbefore defined; and thereafter optionally converting  $\text{R}_1'$ ,  $\text{R}_2'$  and/or Z' to another group or atom  $\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$  or Z; and optionally forming a pharmaceutically acceptable salt of the resultant compound of formula (I).

Examples of leaving groups  $\text{Q}_1$ , displaceable by a nucleophile, include halogen such as chloro and bromo,  $\text{C}_1$ -4 alkoxy, such as  $\text{CH}_3\text{O}$  and  $\text{C}_2\text{H}_5\text{O}$ -,  $\text{PhO}$ -, activated hydrocarbyloxy, such as  $\text{Cl}_5\text{C}_6\text{O}$ - or  $\text{Cl}_3\text{CO}$ -, or a nitrogen-linked heterocycle, such as imidazole.

If a group  $\text{Q}_1$  is a halide, then the reaction is preferably carried out at non-extreme temperatures in an inert non-hydroxylic solvent, such as benzene, dichloromethane, toluene, diethyl ether, tetrahydrofuran (THF) or



-7-

dimethylformamide (DMF). It is also preferably carried out in the presence of an acid acceptor, such as an organic base, in particular a tertiary amine, such as triethylamine, trimethylamine, pyridine or picoline, some of which can also function as the solvent. Alternatively, the acid acceptor can be inorganic, such as calcium carbonate, sodium carbonate or potassium carbonate. Temperatures of 0°-100°C, in particular 10-80°C are suitable.

- 10 If a group  $Q_1$  is  $C_{1-4}$  alkoxy, phenoxy or activated hydrocarbyloxy then the reaction is preferably carried out in an inert polar solvent, such as toluene ordimethylformamide. It is also preferred that the group  $Q_1$  is  $Cl_3CO-$  and that the reaction is carried out in toluene at  
15 reflux temperature.

When  $L$  is O the compound of formula (III) may be in the form of a reactive derivative thereof, which is often a salt, such as the lithium, sodium or potassium salt.

20

It will be apparent that compounds of the formula (I) containing an  $R_1$  or  $R_2$  group which is convertible to another such group are useful novel intermediates. i.e. a hydrogen substituent is convertible to a halogen substituent by  
25 halogenation using conventional halogenating agents.

- $Z'$  when other than  $Z$  may be wherein  $R$  is replaced by  $R'$  which is a hydrogenolysable protecting group which is benzyl optionally substituted by one or two groups selected from  
30 halo,  $C_{1-4}$  alkoxy and  $C_{1-4}$  alkyl. Such benzyl groups may, for example, be removed, when  $R_1/R_2$  is not halogen, by conventional transition metal catalysed hydrogenolysis to give compounds of the formula (I) wherein  $R$  is hydrogen.

- 35 This invention also provides a further process for the preparation of a compound of the formula (I) wherein  $R$  is

methyl or a pharmaceutically acceptable salt thereof, which comprises N-methylating a compound of formula (I) wherein R is hydrogen, and optionally forming a pharmaceutically acceptable salt of the resulting compound of the formula (I). In this further process of the invention 'N-methylation' may be achieved by reaction with a compound  $\text{CH}_3\text{Q}_3$  wherein  $\text{Q}_3$  is a leaving group.

Suitable values for  $\text{Q}_3$  include groups displaced by nucleophiles such as Cl, Br, I,  $\text{OSO}_2\text{CH}_3$  or  $\text{OSO}_2\text{C}_6\text{H}_4\text{PCH}_3$ , preferably Cl, Br or I.

The reaction may be carried out under conventional alkylation conditions for example in an inert solvent such as dimethylformamide in the presence of an acid acceptor such as potassium carbonate. Generally the reaction is carried out at non-extreme temperature such as at ambient or slightly above.

Alternatively, 'N-methylation' may be effected under conventional reductive alkylation conditions.

Interconverting R in the compound of the formula (III) before coupling with the compound of the formula (II) is also possible. Such interconversions are effected conveniently under the above conditions. It is desirable to protect any amine function with a group readily removable by acidolysis such as a  $\text{C}_2$ -7 alkanoyl group, before R/Z interconversion.

30

It is often convenient in the preparation of such a compound of formula (III) to prepare the corresponding compound wherein the methyl group is replaced by alkoxy carbonyl. Such compounds may then be reduced using a strong reductant such as lithium aluminium hydride to the corresponding

compound of formula (II).

The compounds of formula (II) are known or are preparable analogously to, or routinely from, known compounds, such as  
5 described in UK 1571278.

Compounds of the formula (III) are generally prepared from the corresponding exocyclic keto derivative of the azabicyclic side chain, prepared by condensation methods,  
10 often using a substituted piperidine.

They may be prepared by processes described in the aforementioned Patent Publications relating to values of the side chain Z.

15

It will be realised that in the compounds of the formula (I) having a tropane, granatane or oxa/thia/aza-granatane side chain, the -COL- linkage has an **endo** orientation with respect to the ring of the bicyclic moiety to which it is  
20 attached. A mixture of **endo** and **exo** isomers of the compound of the formula (I) may be synthesised non-stereospecifically and the desired isomer separated conventionally therefrom e.g. by chromatography; or alternatively the **endo** isomer may  
25 if desired be synthesised from the corresponding **endo** form of the compound of the formula (II). Corresponding geometric isomeric pairs are possible for the isoquinuclidine, isogranatane, oxa/thia-isogranatane and isotropane side chains.

30 Pharmaceutically acceptable salts of the compounds of this invention may be formed conventionally.

The salts may be formed for example by reaction of the base compound of formula (I) with a pharmaceutically acceptable  
35 organic or inorganic acid.

-10-

The compounds of the present invention are 5-HT<sub>3</sub> receptor antagonists and it is thus believed may generally be used in the treatment or prophylaxis of pain, emesis, CNS disorders and gastrointestinal disorders. Pain includes migraine, cluster headache, trigeminal neuralgia and visceral pain; emesis, includes, in particular, that of preventing vomiting and nausea associated with cancer therapy, post-operative emesis, and nausea associated with migraine. Examples of such cancer therapy include that using cytotoxic agents, such as platinum complexes including cisplatin, and also doxorubicin and cyclophosphamide, particularly cisplatin; and also radiation treatment. CNS disorders include anxiety, psychosis, cognitive disorders such as senile dementia and age associated memory impairment (AAMI), and drug dependence. Gastrointestinal disorders include irritable bowel syndrome and diarrhoea.

5-HT<sub>3</sub> receptor antagonists may also be of potential use in the treatment of obesity, arrhythmia, and/or disorders associated with myocardial instability.

The invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Such compositions are prepared by admixture and are usually adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusible solutions or suspensions or suppositories. Orally administrable compositions are preferred, since they are more convenient for general use.

Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional

-11-

excipients such as binding agents, fillers, diluents, tableting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art, for example with  
5 an enteric coating.

Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch  
10 derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate.

Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate. Oral liquid preparations may be in  
15 the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending  
20 agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may  
25 include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

30 Oral liquid preparations are usually in the form of aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs or are presented as a dry product for reconstitution with water or other suitable vehicle before use. Such  
35 liquid preparations may contain conventional additives such

-12-

as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and flavouring or colouring agents.

- 5 The oral compositions may be prepared by conventional methods of blending, filling or tableting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, 10 conventional in the art.

For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle 15 and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.

- Advantageously, adjuvants such as a local anaesthetic, 20 preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.

- 25 Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure of ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is 30 included in the composition to facilitate uniform distribution of the compound of the invention.

- The invention further provides a method of treatment or prophylaxis of pain, emesis, CNS disorders and/or 35 gastrointestinal disorders in mammals, such as humans, which comprises the administration of an effective amount of a

-13-

compound of the formula (I) or a pharmaceutically acceptable salt thereof.

An amount effective to treat the disorders herein- before  
5 described depends on the relative efficacies of the  
compounds of the invention, the nature and severity of the  
disorder being treated and the weight of the mammal.  
However, a unit dose for a 70kg adult will normally contain  
0.05 to 1000mg for example 0.5 to 500mg, of the compound of  
10 the invention. Unit doses may be administered once or more  
than once a day, for example, 2, 3 or 4 times a day, more  
usually 1 to 3 times a day, that is in the range of  
approximately 0.0001 to 50mg/kg/day, more usually 0.0002 to  
25 mg/kg/day.


15 No adverse toxicological effects are indicated within the  
aforementioned dosage ranges.

The invention also provides a compound of formula (I) or a  
20 pharmaceutically acceptable salt thereof for use as an  
active therapeutic substance, in particular for use in the  
treatment of pain, emesis, CNS disorders and/or  
gastrointestinal disorders.

25 The following Examples illustrate the preparation of  
compounds of formula (I).

Example 1

endo-N-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-7-chloro-1,4-benzodioxan-5-carboxamide (E1)



A solution of 7-chloro-1,4-benzodioxan-5-carboxylic acid (UK patent 1,571,278, Societe D'Etudes Scientifiques et Industrielles de L'Ile-de-France) (0.25g) in  $\text{SOCl}_2$  (5 mL) was stirred at room temperature for 2h. The reaction mixture was evaporated to dryness and re-evaporated with xylene (2 x 20 mL). The residue was dissolved in  $\text{CH}_2\text{Cl}_2$  (20 mL) and treated with a solution of endo-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine (0.2g) in  $\text{CH}_2\text{Cl}_2$  (10 mL). After standing at room temperature overnight, the reaction mixture was washed with sat.  $\text{NaHCO}_3$  (50 mL), dried ( $\text{K}_2\text{CO}_3$ ) and evaporated to dryness. The residue was purified by column chromatography ( $\text{Al}_2\text{O}_3$ , eluting with  $\text{CH}_2\text{Cl}_2$ ) to give the title compound, converted to its HCl salt with ethanolic HCl, precipitation with  $\text{Et}_2\text{O}$ . (0.31 g).

$^1\text{H}$  NMR ( $\text{d}^6\text{-DMSO}$ )  $\delta$  8.40, 8.20 (2-d, 1H)

7.10 (s, 2H)

4.65-4.15 (m, 5H including 4.30, brs, 4H)

3.65-3.45 (m, 2H)

2.81, 2.79 (2-s, 3H)

2.55-2.30 (m, 4H)

2.20-1.95 (m, 2H)

1.82-1.53 (m, 2H)

1.55-1.35 (m, 2H)




-15-

Prepared similarly was:

Example 2

5 endo-N-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-  
1,3-benzodioxole-4-carboxamide (E2)



<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.51 (d, 1H)

6.88 (d, 1H)

6.72 (brd, 1H)

6.13 (s, 2H)

4.58-4.38 (m, 1H)

3.09 (brd, 2H)

2.60-2.40 (m, 5H including 2.50 s, 3H)

1.98 (brd 3H)

1.59-1.42 (m, 1H)

1.31 (dt, 2H)

1.03 (brd, 2H)

5-HT<sub>3</sub> Receptor Antagonist Activity

Compounds are evaluated for antagonism of the von Bezold-Jarisch reflex evoked by 5-HT in the anaesthetised rat according to the following method:

Male rats 250-350g, are anaesthetised with urethane (1.25g/kg intraperitoneally) and blood pressure and heart rate are recorded as described by Fozard J.R. et al., J. Cardiovasc. Pharmacol. 2, 229-245 (1980). A submaximal dose of 5-HT (usually 6µg/kg) is given repeatedly by the intravenous route and changes in heart rate quantified. Compounds are given intravenously and the concentration required to reduce the 5-HT-evoked response to 50% of the control response (ED<sub>50</sub>) is then determined.


The compounds of the Examples are both active at a dose of 10µg/kg i.v.

Claims

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:

5

10



(I)

wherein

- R<sub>1</sub> is hydrogen, halo, nitro, amino, C<sub>1-6</sub> alkyl or C<sub>1-6</sub> alkoxy;
- R<sub>2</sub> is halo, C<sub>1-6</sub> alkyl or C<sub>1-6</sub> alkoxy;
- A is (poly)methylene of 1-3 carbon atoms, optionally substituted by one or two C<sub>1-6</sub> alkyl group(s);
- L is O or NH; and
- Z is a di-azacyclic or azabicyclic side chain; having 5-HT<sub>3</sub> receptor antagonist activity.

2. A compound according to claim 1 wherein R<sub>1</sub> is hydrogen and R<sub>2</sub> is chloro or bromo.

25


3. A compound according to claim 1 or 2 wherein O-A-O is methylenedioxy or ethylenedioxy.

4. A compound according to any one of claims 1 to 3 wherein the side chain Z is tropane, granatane, oxa/thia/aza-granatane, quinuclidine, isoquinuclidine, isogranatane, oxa/thia-isogranatane or isotropane.

30

-18-

5. A compound according to claim 4 wherein Z is tropane, oxagranatane or azagranatane.
6. A compound according to any one of claims 1 to 5 wherein L is NH.
7. **endo**-N-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-7-chloro-1,4-benzodioxan-5-carboxamide.
- 10 8. **endo**-N-(9-Methyl-9-azabicyclo[3.3.1]nonan-3-yl)-6-chloro-1,3-benzodioxole-4-carboxamide.
9. A pharmaceutically acceptable salt of a compound according to claim 7 or 8.
- 15 10. A compound according to claim 1 substantially as defined herein with reference to the Examples.
11. A process for the preparation of a compound according to  
20 claim 1, or a pharmaceutically acceptable salt thereof, which process comprises reacting a compound of formula (II):



(II)

30 with a compound of formula (III):

HLZ'

(III)

or a reactive derivative thereof, when L is O;

wherein  $R_1'$ ,  $R_2'$  and/or  $Z'$  are  $R_1$ ,  $R_2$  and/or  $Z$  respectively or groups or atoms convertible thereto;  $Q_1$  is a leaving group; and the remaining variables are as hereinbefore defined; and thereafter optionally converting  $R_1'$ ,  $R_2'$  and/or  $Z'$  to another group or atom  $R_1$ ,  $R_2$ ,  $R_3$  or  $Z$ ; and optionally forming a pharmaceutically acceptable salt of the resultant compound of formula (I).

10

12. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

15 13. A method of treatment or prophylaxis of pain, emesis, CNS disorders and/or gastrointestinal disorders in mammals, such as humans, which comprises the administration of an effective amount of a compound according to claim 1.

20 14. A compound according to any one of claims 1 to 11 for use as an active therapeutic substance.


15. A compound according to any one of claims 1 to 11 for use in the treatment of pain, emesis, CNS disorders and/or  
25 gastrointestinal disorders.

16. The use of a compound according to any one of claims 1 to 11 in the manufacture of a medicament for the treatment and/or prophylaxis of pain, emesis, CNS disorders and/or  
30 gastrointestinal disorders.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 91/02173

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>9</sup>			
According to International Patent Classification (IPC) or to both National Classification and IPC			
Int.Cl.5	C 07 D 451/00	C 07 D 451/04	C 07 D 451/06
C 07 D 451/14	C 07 D 453/02	C 07 D 453/06	C 07 D 487/08
C 07 D 498/08	A 61 K 31/395	A 61 K 31/435	
<b>II. FIELDS SEARCHED</b>			
Minimum Documentation Searched <sup>7</sup>			
Classification System	Classification Symbols		
Int.Cl.5	C 07 D 451/00 C 07 D 498/00	C 07 D 453/00 A 61 K 31/00	C 07 D 487/00
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>			
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>			
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>		Relevant to Claim No. <sup>13</sup>
X	EP,A,0083737 (BEECHAM GROUP PLC) 20 July 1983, see abstract; claims 1,11-13; page 22, lines 12-22 ---		1-4,6, 11,12, 14-16
X	CH,A, 651561 (DELANDE S.A.) 30 September 1985, see abstract; claims 1,13 ---		1-3,6
X	GB,A,1571447 (SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE) 16 July 1980, see claims 1,15,17,92-95 ---		1-6,12, 14-16
X	EP,A,0377967 (BEECHAM GROUP PLC) 18 July 1990, see claims 1,2,11,14,15,17 --- -/-		1,4-6, 11,12, 14-16
<sup>9</sup> Special categories of cited documents : <sup>10</sup> <sup>A</sup> document defining the general state of the art which is not considered to be of particular relevance <sup>E</sup> earlier document but published on or after the international filing date <sup>L</sup> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) <sup>O</sup> document referring to an oral disclosure, use, exhibition or other means <sup>P</sup> document published prior to the international filing date but later than the priority date claimed <sup>T</sup> later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention <sup>X</sup> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step <sup>Y</sup> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu- ments, such combination being obvious to a person skilled in the art. <sup>&amp;</sup> document member of the same parent family			
<b>IV. CERTIFICATION</b>			
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report	
17-02-1992		24. 03. 92	
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer  Danielle van der Haas	

Form PCT/ISA/210 (second sheet) (January 1985)

## III. DOCUMENTS CONSIDERED TO BE RELEVANT

(CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	EP,A,0041817 (BEECHAM GROUP LIMITED) 16 December 1981, see abstract; claims 1,8,13 ---	1-6,11, 12,14- 16
X	EP,A,0226267 (BEECHAM GROUP PLC) 24 June 1987, see abstract; claims 1,5,6,9,13-15 -----	1-4,6, 11,12, 14-16

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 13 because they relate to subject matter not required to be searched by this Authority, namely:

See PCT Rule 39.1 (iv)  
Methods for treatment of the human or animal body by surgery  
or therapy, as well as diagnostic methods.

2. ☐ Claim numbers \_\_\_\_\_, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers \_\_\_\_\_, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



ANHANG  
zum internationalen Recherchen-  
bericht über die internationale  
Patentanmeldung Nr.

ANNEX  
to the International Search  
Report to the International Patent  
Application No.

PCT/GB91/02173 SAE 54087

ANNEXE  
au rapport de recherche inter-  
national relatif à la demande de brevet  
international n°

In diesen Anhang sind die Mitglieder  
der Patentfamilien der in obenge-  
nannten internationalen Recherchenbericht  
angeführten Patentdokumente angegeben.  
Diese Angaben dienen nur zur Unter-  
richtung und erfolgen ohne Gewähr.

This Annex lists the patent family  
members relating to the patent documents  
cited in the above-mentioned inter-  
national search report. The Office is  
in no way liable for these particulars  
which are given merely for the purpose  
of information.

La présente annexe indique les  
membres de la famille de brevets  
relatifs aux documents de brevets cités  
dans le rapport de recherche inter-  
national visé ci-dessus. Les renseigne-  
ments fournis sont donnés à titre indica-  
tif et n'engagent pas la responsabilité  
de l'Office.

In Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP-A1- 83737	20-07-83	AU-A1-91538/82	23-06-83
		ES-A1- 518204	01-02-84
		ES-A1- 518204	29-02-84
		ES-A1- 84022399	16-04-84
		JP-A2-58110586	01-07-83
		AU-A1-84932782	23-12-82
		DE-CO- 3268378	22-02-86
		EP-A1- 67615	22-12-82
		EP-B1- 67615	08-01-84
		JP-A2-58032878	25-02-84
		US-A - 4499099	28-09-83
		ZA-A - 8209233	12-01-83
		EP-A1- 513160	01-08-83
		EP-A1- 513160	31-08-83
		ES-A1- 8307803	01-11-83
		ES-A1- 520633	01-04-84
		ES-A1- 520633	02-09-84
		ES-A1- 520633	01-07-84
		JP-A2-58010580	21-01-83
		US-A - 44459300	10-07-84
		ZA-A1- 83390782	06-01-83
		EP-A1- 513561	05-01-83
		EP-A1- 513561	01-07-83
		EP-A1- 513561	29-07-83
		ES-A1- 8307244	16-10-83
		JP-A2-58010579	21-04-83
		ZA-A - 8204579	12-01-83
		JP-A1- 69481	21-11-81
		JP-A2-58010578	27-04-83
		ZA-A - 8204238	

CH-A5- 651561

BE-A4- 890962	03-05-82
CA-A1- 1209574	12-08-86
CH-A - 651561	30-08-86
DE-A1- 3144183	13-08-83
DE-C2- 307383	03-01-83
ES-A1- 507394	01-02-83
ES-A1- 507394	11-02-83
FR-A2- 8301979	01-04-83
FR-A2- 2493848	14-03-82
FR-B2- 2493848	16-05-86
GB-A1- 2088364	09-06-82
GB-B2- 2088364	31-10-84
IT-AO- 8124853	31-11-81
IT-A - 1140040	24-09-86
JP-A2-57108090	05-07-82
JP-A4- 63044733	06-09-88
LU-A1- 83737	01-09-83
NL-A - 8105042	01-06-82
SE-A - 8106425	08-05-82
SE-B - 448457	23-02-87
SE-C - 448457	02-07-87
US-A - 4434170	28-02-84
ZA-A - 810775	27-10-82
BE-A1- 890979	04-05-83
LU-A1- 82083	10-09-81
BE-A1- 890979	04-05-82
CA-A1- 1175023	25-09-84
CA-A2- 1175024	25-09-84
CA-A2- 1179658	18-12-84

DE-C0-	3177004	30-04-89
DK-A-	933782	30-06-82
EP-A1-	640358	10-11-80
EP-B1-	640358	15-03-89
EP-A1-	640358	01-02-89
EP-A1-	640358	29-02-89
EP-A1-	83002474	16-04-89
EP-A1-	83002474	16-12-89
EP-A1-	83002474	14-01-84
EP-A1-	8401326	01-03-84
IT-A0-	8124855	04-11-81
IT-A-	1140261	24-09-86
JP-T2-	57501823	14-10-82
JP-B4-	2025626	05-06-90
US-A-	4316576	23-03-89
WD-A1-	8201480	12-07-87
AL-B2-	54610480	23-02-89
BR-A1-	8811134	14-07-80
CA-A1-	1130286	24-08-82
CA-A2-	1160227	10-01-84
CH-A-	646969	22-12-84
CH-A-	647520	31-01-85
DE-A1-	3001328	24-07-80
DE-C2-	3001328	08-06-89
EP-A1-	487721	16-06-81
EP-A0-	487721	21-08-81
FR-B2-	2476088	04-11-83
GB-A1-	0423523	04-09-80
GB-A1-	0423523	04-03-81
GB-B2-	0423523	07-04-83
GB-B2-	0423523	13-04-83
IT-A0-	8019071	08-01-80
IT-A0-	8024713	17-03-80
JP-A2-	1148801	03-12-86
JP-A2-	85108871	17-12-81
JP-A2-	85116487	28-04-84
JP-B4-	60059915	27-12-85
MX-U-	6529	28-06-85
NL-A-	8000277	18-07-80
NL-A-	80005774	30-01-81
SE-A-	8000068	17-07-80
SE-B-	431984	12-03-84
SE-B-	431984	23-04-84
SE-B-	444941	20-05-86
SE-B-	444941	28-08-86
US-A-	4321578	23-03-82
US-A-	4329466	11-05-82
US-A-	4424358	03-01-84
US-A-	4471120	11-09-84
US-A-	4536580	20-08-85
FR-A1-	33446823	14-08-80
FR-B1-	33446823	28-11-80
ZA-A-	8000160	28-01-81
CA-A2-	1179024	25-09-84
CA-A2-	1179658	18-12-84
DK-A-	933782	30-06-82
DE-C0-	3177004	30-04-89
EP-A1-	640358	10-11-80
EP-B1-	640358	15-03-89
JP-T2-	57501823	14-10-82
JP-B4-	2025626	05-06-90
AL-B2-	54610480	23-02-89
AL-B2-	54610480	04-10-84

GB-A - 1571447

16-07-80

AR-A1-	219709	15-09-80
AT-A-	5696777	15-01-80
AT-B-	3358034	11-08-80
AU-A1-	2750777	08-03-79
BE-B2-	86116033	14-06-79
BE-A1-	857380	01-02-78
BE-A3-	36496	15-11-84
CA-A1-	1114371	15-12-81
CH-A-	629198	15-04-82
CS-B2-	316246	29-10-82
DD-C-	133237	20-12-78
DE-A1-	734270	16-02-78
DE-C2-	734270	17-05-90
DE-C2-	734270	21-06-90
DK-A-	4469777	05-06-78
DK-B-	152366	23-02-88
ES-A-	12716	20-09-79
ES-A1-	461175	01-12-78
ES-A5-	461175	02-01-79

PTI-A	-	7723362	05	-02	-78
PTI-B	-	6393862	01	-03	-78
PTI-C	-	6393862	01	-03	-78
PTI-D	-	6393862	01	-03	-78
PTI-E	-	6393862	01	-03	-78
PTI-F	-	6393862	01	-03	-78
PTI-G	-	6393862	01	-03	-78
PTI-H	-	6393862	01	-03	-78
PTI-I	-	6393862	01	-03	-78
PTI-J	-	6393862	01	-03	-78
PTI-K	-	6393862	01	-03	-78
PTI-L	-	6393862	01	-03	-78
PTI-M	-	6393862	01	-03	-78
PTI-N	-	6393862	01	-03	-78
PTI-O	-	6393862	01	-03	-78
PTI-P	-	6393862	01	-03	-78
PTI-Q	-	6393862	01	-03	-78
PTI-R	-	6393862	01	-03	-78
PTI-S	-	6393862	01	-03	-78
PTI-T	-	6393862	01	-03	-78
PTI-U	-	6393862	01	-03	-78
PTI-V	-	6393862	01	-03	-78
PTI-W	-	6393862	01	-03	-78
PTI-X	-	6393862	01	-03	-78
PTI-Y	-	6393862	01	-03	-78
PTI-Z	-	6393862	01	-03	-78
PTI-AA	-	6393862	01	-03	-78
PTI-AB	-	6393862	01	-03	-78
PTI-AC	-	6393862	01	-03	-78
PTI-AD	-	6393862	01	-03	-78
PTI-AE	-	6393862	01	-03	-78
PTI-AF	-	6393862	01	-03	-78
PTI-AG	-	6393862	01	-03	-78
PTI-AH	-	6393862	01	-03	-78
PTI-AI	-	6393862	01	-03	-78
PTI-AJ	-	6393862	01	-03	-78
PTI-AK	-	6393862	01	-03	-78
PTI-AL	-	6393862	01	-03	-78
PTI-AM	-	6393862	01	-03	-78
PTI-AN	-	6393862	01	-03	-78
PTI-AO	-	6393862	01	-03	-78
PTI-AP	-	6393862	01	-03	-78
PTI-AQ	-	6393862	01	-03	-78
PTI-AR	-	6393862	01	-03	-78
PTI-AS	-	6393862	01	-03	-78
PTI-AT	-	6393862	01	-03	-78
PTI-AU	-	6393862	01	-03	-78
PTI-AV	-	6393862	01	-03	-78
PTI-AW	-	6393862	01	-03	-78
PTI-AX	-	6393862	01	-03	-78
PTI-AY	-	6393862	01	-03	-78
PTI-AZ	-	6393862	01	-03	-78
PTI-BA	-	6393862	01	-03	-78
PTI-BB	-	6393862	01	-03	-78
PTI-BC	-	6393862	01	-03	-78
PTI-BD	-	6393862	01	-03	-78
PTI-BE	-	6393862	01	-03	-78
PTI-BF	-	6393862	01	-03	-78
PTI-BG	-	6393862	01	-03	-78
PTI-BH	-	6393862	01	-03	-78
PTI-BI	-	6393862	01	-03	-78
PTI-BJ	-	6393862	01	-03	-78
PTI-BK	-	6393862	01	-03	-78
PTI-BL	-	6393862	01	-03	-78
PTI-BM	-	6393862	01	-03	-78
PTI-BN	-	6393862	01	-03	-78
PTI-BO	-	6393862	01	-03	-78
PTI-BP	-	6393862	01	-03	-78
PTI-BQ	-	6393862	01	-03	-78
PTI-BR	-	6393862	01	-03	-78
PTI-BS	-	6393862	01	-03	-78
PTI-BT	-	6393862	01	-03	-78
PTI-BU	-	6393862	01	-03	-78
PTI-BV	-	6393862	01	-03	-78
PTI-BW	-	6393862	01	-03	-78
PTI-BX	-	6393862	01	-03	-78
PTI-BY	-	6393862	01	-03	-78
PTI-BZ	-	6393862	01	-03	-78
PTI-CA	-	6393862	01	-03	-78
PTI					

EP-A2- 377967 18-07-90

AU-A1-4	6081/89
CA-AA-	2005131
DK-A0-	6252/89
DK-A-	6252/89
EP-A3-	377967
GB-A0-	8829079
JP-A2-	2202890
ZA-A-	8909434

EP-A1- 41817 16-12-81

JP-A2-57031689  
US-A - 4352802

BNSDOCID: <WO 9210494A1> 157

24-06-87

-----  
AU-A1-60274/86

22-01-87

AU-B2-	594351	08-03-90
DK-A0-	3408786	17-07-86
DK-A-	3408786	20-01-87
ES-AF-	2000524	01-03-88
GB-A0-	8518236	29-08-85
JP-A2-	62030785	09-02-87
NZ-A-	216880	27-09-89
PT-A-	62016	01-08-86
US-A-	4826839	02-08-89
US-A-	4883874	28-11-89
ZA-A-	8605328	24-06-87
ES-YA-	1000319	16-07-88

---